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Aims Comorbidity, such as myocardial infarction, diabetes, and renal failure, plays a pivotal role in the prognosis of a patient
with arrhythmias. However, data on the prognostic impact of comorbiditiy in heart failure patients with cardiac resyn-
chronization therapy and deﬁbrillation (CRT-D) are scarce. The purpose of this study was to determine the impact of
comorbidity on survival in CRT-D patients.
Methods
and results
The study population consisted of 463 heart failure patients who received a CRT-D between 1999 and 2008 in Rot-
terdam and Basel. The Charlson comorbidity index (CCI) is often used as an adjusting variable in prognostic models.
The Cox proportional hazards analysis was performed to determine the independent effect of comorbidity on sur-
vival. During a median follow-up of 30.5 months, 85 patients died. Mortality rates at 1 and 7 years were 6.3 and 32.3%.
Cumulative incidence of implantable cardioverter deﬁbrillator (ICD) therapy at 7 years was 50%, and death without
ICD therapy was observed in 9% of patients. At least three comorbid conditions were observed in 81% of patients.
Patients who died had a higher CCI score compared with those who survived (3.9+1.5 vs. 2.9+1.5; P , 0.001). An
age-adjusted CCI score ≥5 was a predictor of mortality (hazard ratio 3.69, 95% CI 2.06–6.60; P , 0.001) indepen-
dent from indication for ICD therapy, and from ICD interventions during the clinical course.
Conclusion Comorbidity is often present in heart failure patients, and a high comorbidity burden was a signiﬁcant predictor of
mortality in CRT-D recipients. Comorbidity cannot predict appropriate ICD therapy. Death without prior ICD
therapy occurs in a minor proportion of patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Data from randomized clinical trials have demonstrated that
implantable cardioverter deﬁbrillators (ICDs) provide a signiﬁcant
reduction in arrhythmic mortality in patients with ischaemic and
non-ischaemic cardiomyopathy, both in primary and secondary
prevention.
1–4 In addition, cardiac resynchronization therapy
(CRT) has been shown to improve symptoms, reduce hospitaliz-
ations, and to reduce mortality in patients with refractory heart
failure (HF).
5–7 Despite the advances in medical therapy, the prog-
nosis of HF patients is poor. Commonly used risk factors that
predict prognosis in ICD recipients with HF include NYHA func-
tional class, QRS width, and left ventricular ejection fraction
(LVEF). However, the majority of patients has more than one
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comorbidity as renal failure and diabetes further inﬂuence the
prognosis of ICD recipients.
8–10 The role of comorbidity in the
short- and long-term prognosis of HF patients implanted with an
ICD capable of cardiac resynchronization therapy (CRT-D) has
not been adequately studied. The Charlson comorbidity index
(CCI) is widely used as an adjustment variable in prognostic
models.
11 The index is based on comorbid conditions and cardio-
vascular risk factors of known prognostic value with varying
assigned weights. The aim of the present study was to determine
whether the pre-implant CCI predicts long-term survival and
whether the CCI has the potential to identify those patients
who would beneﬁt less from CRT-D implantation.
Methods
Study population
Two prospective ICD registries of the cardiology departments of the
Erasmus MC and the University Hospital of Basel were the basis for
this study. Out of these registries, we identiﬁed all patients who
received a CRT-D. The following selection criteria for CRT were
applied: symptomatic HF despite optimal drug therapy, impaired
LVEF (LVEF ≤35%), inter- or intra-ventricular conduction delay
(QRS duration ≥120 ms), and LV end-diastolic diameter .55 mm.
Indications for ICD therapy were dichotomized into primary or sec-
ondary prevention. Secondary prevention was deﬁned as cardiac
arrest without transient or reversible cause or spontaneous sympto-
matic sustained ventricular arrhythmias. Primary prevention as indi-
cation for ICD therapy was deﬁned as the presence of LVEF ≤35%
with ischaemic or non-ischaemic cardiomyopathy in the absence of a
history of cardiac arrest or sustained ventricular arrhythmia.
12 As a
certain period of follow-up was warranted, only patients who were fol-
lowed for at least 12 months were eligible for the analysis.
All implanted devices were capable of storing intracardiac electro-
grams. A two-zone conﬁguration was programmed in 83% of patients.
The mean ventricular tachycardia detection rate was 353+24 ms, the
mean ventricular ﬁbrillation detection rate was 284+15 ms. For all
devices, antitachycardia pacing in combination with cardioversion/deﬁ-
brillation therapy features was activated. For resynchronization
therapy, the atrio-ventricular delay was optimized by 2D echocardio-
graphy to provide the longest diastolic ﬁlling time and the highest
left ventricular outﬂow tract velocity timed integral.
Construction of the comorbidity index
Comorbidity as present before ICD implantation was identiﬁed via
patient history, laboratory values, and review of patients’ clinical
data. For all patients, the renal function was assessed by estimating
the baseline glomerular ﬁltration rate (eGFR) using the abbreviated
Modiﬁcation of Diet in Renal Disease (MDRD) Study equation:
eGFR (mL/min/1.73 m
2 of body surface area) ¼ 186 × (serum creati-
nine in mg/dL)
21.154 × (age)
20.203 × 0.742 in female subjects.
13
Impaired renal function was deﬁned as an eGFR ,60 mL/min/
1.73 m
2 according to practice guidelines.
14 Comorbidity was quantiﬁed
using the CCI, which is based on 17 different categories of comorbidity
with varying assigned weights. The comorbid conditions included in
our abbreviated CCI model were myocardial infarction, cerebrovascu-
lar disease, chronic obstructive pulmonary disease, diabetes, peripheral
vascular disease, renal failure, and any malignancy excluding metastatic
tumours. The comorbidity index was calculated by assigning a weight
of 2 to renal failure and any malignancy, and a weight of 1 to the
other comorbid conditions. The comorbidity score for each patient
is the arithmetic sum of the value assigned to each identiﬁed comorbid
condition. Age is also a risk factor for mortality independent from each
comorbid condition. To account for the effects of increasing age, the
comorbidity score was adjusted by adding one point to the score
for each decade of life over the age of 50 at time of implantation.
Follow-up
Follow-up started at the time of ICD implantation. In Basel, patients
were followed at 1, 3, and 6 months after implantation, and then at
6-month intervals. In Rotterdam, patients were seen at 10 days, 3, 6,
9, and 12 months after implantation, and then also at 6-month inter-
vals. All patients were advised to contact the outpatient clinic as
soon as possible after symptomatic events. At each visit, arrhythmic
events were retrieved from the device’s memory. The stored electro-
grams were analysed to classify the arrhythmias responsible for trigger-
ing ICD therapy. Appropriate ICD therapy was deﬁned as an
antitachycardia pacing therapy or shock for an arrhythmia determined
to be either ventricular tachycardia or ventricular ﬁbrillation.
Deaths were classiﬁed according to a modiﬁed Hinkle–Thaler
system.
15,16Theprimaryendpointwasall-causemortality.Thesecondary
endpoint was time from ICD implantation until the ﬁrst appropriate ICD
therapy or death (e.g. death without prior appropriate ICD therapy).
Statistical analysis
All statistics were performed using SPSS (version 16.0) for Windows
(SPSS Inc., Chicago, IL, USA). Continuous variables were expressed
as mean+SD, if normally distributed, or otherwise by median and
interquartile range (IQR). Data were compared with Student’s t-test
or the Mann–Whitney U test, when appropriate. Categorical data
were expressed as percentages and compared with Fisher’s exact
test. Simultaneous comparison of .2 mean values was performed
by one-way analysis of variance. Cumulative actuarial survival rates
were calculated according to the Kaplan–Meier method. Differences
between pairs of actuarial curves were tested by the log-rank test. Uni-
variate analysis was used to identify variables associated with mortality
after ICD implantation. Baseline clinical variables and previously ident-
iﬁed variables associated with mortality (P , 0.10) were entered in the
multivariate Cox proportional hazards analysis. The proportional
hazards assumption was checked graphically by log survival vs. log
(2log survival distribution function). In addition, the proportional
hazards assumption for all variables was tested using Schoenfeld
residuals. Hazard ratios (HRs) with corresponding 95% conﬁdence
intervals (CIs) are reported. A two-tailed P-value of 0.05 was con-
sidered as signiﬁcant.
Results
Patient characteristics
The baseline characteristics of the study population are presented
in Table 1. The majority of patients was aged ,65 years (55%) with
a mean age of 62+11 years. Most CRT-D recipients were men
(75%). The mean LVEF was 24+7%, and the mean QRS duration
was 165+30 ms. Three hundred thirty-four patients (72%) were
in NYHA class III. Ischaemic aetiology of HF was present in 50% of
the patients. Atrial ﬁbrillation was present in 18% of patients. In the
entire study population, the number of comorbid conditions
ranged from one to seven per patient. Comorbidity was
common among HF patients, with 81% of the patients having at
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comorbid conditions were renal disease, diabetes mellitus, cer-
ebrovascular disease, and chronic obstructive pulmonary disease
(Table 2). The prevalence of comorbidity increased with older
age (all P-value trends ,0.001). The comorbidity index scores
ranged from 1 to 9, with a mean of 3.1+1.5.
Comorbidity and mortality
During a median follow-up of 30.5 months (IQR: 18.2–50.7
months), a total of 85 patients (18%) reached the primary end-
point. Of the 85 deaths, 66 (78%) were classiﬁed as cardiac and
7 (8%) as non-cardiac. The cause of death was unknown in 12
cases. Figure 1 presents the cumulative mortality for the studied
population. The overall mortality rates were 6.3, 12.9, and 32.3%,
at 1, 2, and 7 years, respectively. At 7 years, mortality rates were
not different between primary and secondary prevention patients
(31 vs. 36%).
Survivors and non-survivors did not differ signiﬁcantly with
respect to gender, LVEF, QRS duration, and pharmacological treat-
ment (ACE-I, diuretics, beta-blocker, and statin). There was a trend
towards a higher prevalence of atrial ﬁbrillation, and use of amio-
darone and digoxin was higher in patients who died, but the differ-
ence was not statistically signiﬁcant (P , 0.10). Regarding the
comorbidity index score, patients who died had a signiﬁcantly
higher CCI score compared with those who survived (3.9+1.5
vs. 2.9+1.5; P , 0.001). Patients who died during long-term
follow-up were signiﬁcantly older (median 67 vs. 62 years, P ,
0.05). Older age at implant is associated with increased mortality
risk. In univariate analysis, the HR for all-cause mortality was
1.92 (95% CI 1.25–2.96; P ¼ 0.003) in those aged ≥65 years.
Accordingly, the CCI scores were adjusted for age to account
for the effects of increasing age by adding one point to the score
for each decade of life over the age of 50. The mean age-adjusted
CCI score for patients who died was signiﬁcantly higher compared
with those who survived (5.9+1.9 vs. 4.7+2.1; P , 0.001).
Figure 2A presents the difference in 2-year mortality rates among
patients according to the cut-off value of age-adjusted CCI score.
Notably, the difference in mortality rate was most prominent
among patients with an age-adjusted CCI ≥5 compared with
those with age-adjusted CCI ,5, whereas among patients with
an age-adjusted CCI ≥7, mortality was slightly higher compared
with those with age-adjusted CCI ,7. The effect of increasing
age-adjusted CCI score on 2-year mortality rates showed an
inverted U-shaped curve (Figure 2B). The 7-year mortality rates
were signiﬁcantly higher for patients with age-adjusted CCI score
≥5 compared with those with age-adjusted CCI score ,5 (42.3
vs. 17.1%; P , 0.001; Figure 3).
Appropriate implantable cardioverter
deﬁbrillator therapy, mortality,
and comorbidity
During follow-up, 149 patients (32%) experienced ICD therapy for
ventricular tachyarrhythmias. The ﬁrst appropriate device therapy
occurred at median interval of 6.9 months (IQR: 1.7–15.0 months)
after implantation. Cumulative event rates for appropriate ICD
therapy were 21.7, 28.5, and 50.4%, at 1, 2, and 7 years, respect-
ively. Patients with a secondary prevention indication were more
likely to receive appropriate ICD therapy compared with
primary prevention (56 vs. 24%, P , 0.001). The 7-year event
rate of appropriate ICD therapy was 66.8% for secondary preven-
tion patients, compared with 39.1% for primary prevention
patients (Figure 4). The event rates of appropriate ICD therapy
were not signiﬁcantly different in both primary and secondary
................................................................................
Table 1 Baseline clinical characteristics of the study
population
Total population
(n 5 463)
Demographic data, n (%)
Male gender 349 (75)
Age (years) 62+11
Clinical data, n (%)
Indication ICD therapy
Primary prevention 346 (75)
Secondary prevention 117 (25)
NYHA class
II 129 (28)
III 334 (72)
Left ventricular ejection fraction (%) 24+7
QRS duration (ms) 165+30
Creatinine (mg/dL) 1.35+0.70
Ischaemic aetiology 233 (50)
History of myocardial infarction 200 (43)
History of bypass surgery 95 (21)
Pharmacological treatment
Amiodarone 135 (29)
Beta-blockers 350 (76)
ACE-inhibitors/ARBs 423 (91)
Diuretics 388 (84)
Digoxin 117 (25)
Statin 245 (53)
................................................................................
Table 2 Prevalence of comorbid conditions
Comorbid conditions Total population
(n 5 463)
Cardiac comorbidities, n (%)
Myocardial infarction 200 (43)
Non-cardiac comorbidities, n (%)
Cerebrovascular disease 59 (13)
Chronic obstructive pulmonary disease 47 (10)
Diabetes 118 (26)
Peripheral vascular disease 17 (4)
Renal disease 236 (51)
Any malignancy (excluding
metastatic tumours)
36 (8)
D.A.M.J. Theuns et al. 64Figure 1 Cumulative mortality for heart failure patients treated with cardiac resynchronization therapy and deﬁbrillation.
Figure 2 Inverted U-shaped curve for mortality. (A) Two-year Kaplan–Meier mortality rates for the groups dichotomized according to the
cut-off value of age-adjusted Charlson comorbidity index score. (B) The corresponding 2-year mortality increase for patients with age-adjusted
Charlson comorbidity index score ≥ cut-off value.
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age-adjusted CCI ,5( Figure 5).
A total of 189 patients (41%) reached the secondary endpoint of
time to ﬁrst appropriate ICD therapy or death. Death without
prior appropriate ICD therapy was observed in 40 patients,
whereas 45 patients received appropriate ICD therapy prior to
death, and 104 patients received appropriate ICD therapy. The
estimated proportion of patients free of appropriate ICD
therapy or death was 40.9% at 7 years. The majority of patients
(85%) who died without prior appropriate ICD therapy had a
primary prevention indication. The 7-year mortality rates
between patients with and without prior appropriate ICD
therapy were signiﬁcantly different (44.9 vs. 21.9%, P , 0.001). In
univariate analysis, appropriate ICD therapy was associated with
an increased risk for all-cause mortality (HR 2.06, 95% CI 1.34–
3.17; P , 0.001).
The multivariate Cox proportional hazard regression analysis
identiﬁed an age-adjusted CCI score ≥5 (HR 3.69, 95% CI
2.06–6.60; P , 0.001) and appropriate device therapy (HR
1.80, 95% CI 1.17–2.77; P ¼ 0.008) as predictors of all-cause
mortality independent from the prevention indication for ICD
therapy. Atrial ﬁbrillation, use of amiodarone and digoxin was
not signiﬁcantly associated with mortality in the multivariate
analysis.
Figure 3 Cumulative mortality rates for the two groups dichotomized according to an age-adjusted Charlson comorbidity index with cut-off
value 5.
Figure 4 Cumulative rates of appropriate device therapy for patients with a primary or secondary prevention indication.
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The present study evaluated the prognostic impact of comorbidity
using an abbreviated modiﬁed CCI in HF patients who received a
CRT-D for primary or secondary prevention of sudden cardiac
death. We found that comorbidity was common in our study
population of HF patients, with 81% of the patients having at
least three comorbid conditions. Comorbidity was signiﬁcantly
associated with mortality after device implantation. Patients with
a high comorbidity burden, deﬁned as an age-adjusted CCI ≥5
had an increased risk for mortality, independent from the preven-
tion indication.
Previous studies have examined factors associated with
increased mortality in ICD recipients. Parkash et al.
17 developed
a risk score using baseline characteristics to predict early mortality
after ICD implantation. Independent factors were age .80 years,
history of atrial ﬁbrillation, renal dysfunction (creatinine 1.8 mg/
dL), and NYHA class III or IV. Patients with two or more of
these factors had an increased risk for early mortality after
device implantation, with renal dysfunction as comorbidity. A
recent analysis of the second Multicenter Automatic Deﬁbrillator
Implantation Trial (MADIT II) demonstrated that a point score
based on clinical variables (age .65 years, diabetes, NYHA class
.II, blood urea nitrogen .28 mg/dL, and non-sinus rhythm) can
identify patients at high risk for death during long-term follow-up.
18
At 6-years follow-up, patients with high risk (at least three risk
factors), medium risk (one to two risk factors), and low risk (no
risk factors) had a cumulative mortality of 68, 43, and 19%,
Figure 5 Cumulative rates of appropriate device therapy for patients dichotomized according to an age-adjusted Charlson comorbidity index
with cut-off value 5 and a primary prevention indication (A) or secondary prevention indication (B).
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19 the prognostic impact of
comorbidities in HF patients treated with an ICD was examined.
In this study, the presence of renal dysfunction, age, and NYHA
functional class predicted mortality. Patients with all of these vari-
ables had an event-free survival of 15% at 1400 days follow-up. The
previous studies identiﬁed renal failure as a predictor of mortality,
next to traditional markers as NYHA functional class and advanced
age. The effect of cardiac and non-cardiac conditions on survival
has been evaluated in a large community-based examination of
ICD recipients.
20 This study revealed that the presence of non-
cardiac comorbidity and prior HF was a signiﬁcant predictor of
death. The adjusted HR for death was 2.98 for patients with at
least three comorbid conditions. In our study all patients had HF,
but consistent results were observed with increased mortality
for those with a high comorbidity burden.
The results of the present study may have implications for the
translation of the expanded indications for ICD therapy from ran-
domized trials into clinical practice. Evidence from randomized
clinical trials indicates that the ICD reduces arrhythmic mortality
in HF patients with ischaemic and non-ischaemic cardiomyopathy,
both in primary and secondary prevention.
1–4 In addition, the efﬁ-
cacy and survival beneﬁts of CRT have been proved in observa-
tional studies as well as in randomized trials.
5,6,21 Taken this
together, the addition of deﬁbrillation to CRT is reasonable, as
the CRT-D targets both HF and arrhythmic mortality. Despite
the effectiveness of terminating ventricular tachyarrhythmias
by the implantable deﬁbrillator, competing non-cardiac comorbid-
ity is associated with increased mortality in ICD patients.
22 Bai
et al.,
23 demonstrated that renal failure and diabetes are strong
independent predictors of mortality in patients treated with
CRT. Both comorbid conditions are incorporated in the Charlson
model as applied in the present study.
The rate of appropriate ICD therapy was twice as likely in sec-
ondary prevention compared with primary prevention. This ﬁnding
is consistent with previous studies.
24,25 In addition, we found
increased mortality in patients who experienced appropriate ICD
therapy. This result is consistent with other published
studies.
26,27 In clinical practice, it is of particular interest to identify
patients who might not beneﬁt from ICD implantation. In our
study, the majority of patients who died prior to appropriate
ICD therapy had a primary prevention indication. Taken all
together, the ﬁndings of this study may assist the clinician contem-
plating ICD insertion as primary prevention. However, it is still a
personal decision about how high the risk of death from non-
cardiac comorbidity should be before ICD therapy is no longer jus-
tiﬁed. Unfortunately, appropriate ICD interventions cannot be pre-
dicted by the comorbidity index.
Study limitations
The present study has some limitations. Even though the design
was non-randomized, data were collected prospectively. Another
possible limitation is the assessment of comorbidity, which was
partly based on administrative data sources. These sources have
a likelihood of underreporting. However, an analysis of administra-
tive data suggested a high degree of speciﬁcity.
28
Conclusion
Comorbidity is common in HF patients with a CRT-D, which has a
major impact on survival. A high comorbidity burden was a signiﬁ-
cant predictor of death in CRT-D recipients. The abbreviated CCI
is a useful and easy tool to assess the burden of comorbidity at
baseline. Our ﬁndings may assist clinicians contemplating ICD
insertion as primary prevention in patients with HF in the presence
of non-cardiac comorbidity. However, further research is still
needed to characterize other speciﬁc comorbid conditions as pre-
dictors of survival, and to predict who will receive appropriate ICD
therapy.
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